Literature DB >> 2115037

Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.

P J Wu1, D M Livermore.   

Abstract

Cultures of Pseudomonas aeruginosa were grown at different rates in a chemostat and challenged continuously or intermittently with ceftazidime, imipenem, meropenem or piperacillin. The killing rate was related to the bacterial growth rate; fast-growing cells being killed more rapidly than slow-growing ones. Mutants that were stably derepressed (i.e. constitutive) for chromosomal beta-lactamase expression were selected when a beta-lactamase inducible (i.e. typical) strain was challenged with ceftazidime or piperacillin. Addition of the beta-lactamase inhibitor tazobactam to piperacillin did not prevent selection. There was a lag of c. 24-48 h post-challenge before totally derepressed mutants were detectable. Once selected, the derepressed organisms were stable and were not outgrown by inducible cells if these were readded in the absence of selective antibiotics. Selection of resistant mutants was not observed with imipenem, despite the known tendency of this drug to select carbapenem-impermeable mutants of P. aeruginosa in vivo. Imipenem, but not ceftazidime or meropenem, caused a significant post-antibiotic effect after single or repeated dosage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115037     DOI: 10.1093/jac/25.6.891

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria.

Authors:  R H Eng; F T Padberg; S M Smith; E N Tan; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; María D Maciá; Olivia Gutiérrez; Carmen Vidal; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.

Authors:  A Nyhlén; B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

4.  Virtual screening of AmpC/β-lactamase as target for antimicrobial resistance in Pseudomonas aeruginosa.

Authors:  Rohit Farmer; Budhayash Gautam; Satendra Singh; Pramod Kumar Yadav; Prashant Ankur Jain
Journal:  Bioinformation       Date:  2010-01-17

5.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 7.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.